{{Rsnum
|rsid=290487
|Gene=TCF7L2
|Chromosome=10
|position=114909731
|Orientation=plus
|GMAF=0.2746
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 67.3 | 31.0 | 1.8
| HCB | 13.1 | 54.7 | 32.1
| JPT | 16.8 | 46.9 | 36.3
| YRI | 90.5 | 9.5 | 0.0
| ASW | 66.7 | 31.6 | 1.8
| CHB | 13.1 | 54.7 | 32.1
| CHD | 16.5 | 44.0 | 39.4
| GIH | 50.5 | 41.6 | 7.9
| LWK | 95.5 | 4.5 | 0.0
| MEX | 60.3 | 39.7 | 0.0
| MKK | 73.7 | 25.6 | 0.6
| TSI | 57.8 | 40.2 | 2.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19509102
|Title=Genetic Variants of TCF7L2 are Associated with Insulin Resistance and Related Metabolic Phenotypes in Taiwanese Adolescents and Caucasian Young Adults
}}

{{omim
|desc=TRANSCRIPTION FACTOR 7-LIKE 2; TCF7L2
|id=602228
|rsnum=290487
}}

{{PMID Auto
|PMID=19718565
|Title=Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with [[polycystic ovary syndrome]] in Chinese women
}}

{{PMID Auto
|PMID=20054294
|Title=KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) Polymorphisms Affect Therapeutic Efficacy of Repaglinide in Chinese Patients With Type 2 Diabetes
}}

{{PharmGKB
|RSID=rs290487
|Name_s=TCF7L2: intronic C>T SNP
|Gene_s=TCF7L2
|Feature=
|Evidence=PubMed ID:20054294
|Annotation=Risk or phenotype-associated allele: T allele. Phenotype: Body mass index was significantly lower (p < 0.030), and cholesterol levels (p < 0.012)) were significantly higher in T2DM patients with the T allele in a comparison of the TT, TC, and CC genotypes. Study size: 259. Study population/ethnicity: Chinese type 2 Diabetes (T2DM) patients. Significance metric(s): p < 0.03. Type of association: GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165291916
}}

{{PharmGKB
|RSID=rs290487
|Name_s=TCF7L2: intronic C>T SNP
|Gene_s=TCF7L2
|Feature=
|Evidence=PubMed ID:20054294
|Annotation=Risk or phenotype-associated allele: T allele. Phenotype: Body mass index was significantly lower (p < 0.030), and cholesterol levels (p < 0.012)) were significantly higher in T2DM patients with the T allele in a comparison of the TT, TC, and CC genotypes. Study size: 259. Study population/ethnicity: Chinese type 2 Diabetes (T2DM) patients. Significance metric(s): p < 0.03. Type of association: GN
|Drugs=repaglinide
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165290950
}}

{{PharmGKB
|RSID=rs290487
|Name_s=TCF7L2: intronic C>T SNP
|Gene_s=TCF7L2
|Feature=
|Evidence=PubMed ID:20054294
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: After 8-week repaglinide treatment, fasting insulin, triglycerides, and low-density lipoprotein cholesterol (LDL-c) were significantly increased in T2DM patients with the TT genotype (n = 14) compared to patients with the CC and TC genotypes combined (n = 26) (p < 0.043), meaning that TT subjects showed improved repaglinide efficacy compared to subjects with the TC and CC genotypes. Study Size: 40. Study population/ethnicity: Chinese type 2 Diabetes (T2DM) patients with uniform genotype with regard to SLCO1B3 (OATP1B1) T521C. Significance metric(s): p < 0.043. Type of association: GN; PD
|Drugs=repaglinide
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165290951
}}

{{PMID Auto
|PMID=22296403
|Title=Common variants of transcription factor 7-like 2 (TCF7L2) are associated with reduced insulin secretion in women with polycystic ovary syndrome
}}

{{PMID|17579206}} Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population.

{{PMID|18097733}} Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects.

{{PMID|18493736}} Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population.

{{PMID|19482368}} Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population.

{{PMID|20161779|OA=1
}} Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort.

{{PMID Auto
|PMID=23041303
|Title=Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs290487
|overall_frequency_n=33
|overall_frequency_d=128
|overall_frequency=0.257812
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23536853
|Title=Association of rs7903146 (IVS3C/T) and rs290487 (IVS3C/T) Polymorphisms in TCF7L2 with Type 2 Diabetes in 9,619 Han Chinese Population
|OA=1
}}

{{PMID Auto
|PMID=23311683
|Title=Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population
|OA=1
}}

{{PMID Auto
|PMID=23558246
|Title=Impacts of TCF7L2 gene polymorphisms on the susceptibility of hepatogenous diabetes and hepatocellular carcinoma in cirrhotic patients
}}

{{PMID Auto
|PMID=23188737
|Title=TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121,174 subjects
}}

{{PMID Auto
|PMID=23010200
|Title=Association of TCF7L2 gene polymorphisms with type 2 diabetes mellitus in Han Chinese population: a meta-analysis.
}}

{{PMID Auto
|PMID=24002895
|Title=Rs290487 of TCF7L2 gene is not associated with type 2 diabetes in Chinese Han population: a case control study and meta-analysis
}}

{{PMID Auto
|PMID=25185411
|Title=Association of rs7903146, rs12255372, and rs290487 polymorphisms in TCF7L2 gene with type 2 diabetes in an Iranian Kurdish ethnic group
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}